Hue Susan Swee-Shan, Iyer Prasad, Toh Luke Han Wei, Jain Sudhanshi, Tan Enrica Ee Kar, Sittampalam Kesavan, Lian Derrick Wen Quan, Chang Kenneth Tou En
Department of Pathology, National University Hospital.
Department of Paediatric Subspecialties, Haematology-Oncology Service, KK Women's and Children's Hospital.
J Pediatr Hematol Oncol. 2018 Mar;40(2):e103-e107. doi: 10.1097/MPH.0000000000000839.
A 3-year-old boy presented with pathologic fracture of the left proximal femur. Magnetic resonance imaging revealed an aggressive expansile bony mass associated with cortical destruction and surrounding myositis. Computed tomography-guided biopsy revealed a monomorphic small round blue cell tumor by histology. CD99 immunoreactivity and low-level EWSR1 gene translocation by break-apart fluorescent in situ hybridization initially favored a diagnosis of Ewing sarcoma and chemotherapy commenced. Subsequent molecular evaluation by an anchored multiplex polymerase chain reaction-based assay (Archer FusionPlex Sarcoma Panel) revealed a nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) gene fusion. The diagnosis was then amended to primary bone ALK-positive anaplastic large cell lymphoma and the chemotherapy regimen was modified accordingly. This report illustrates the value of this molecular assay in establishing the correct diagnosis of a very rare malignancy masquerading as another tumor type.
一名3岁男孩因左股骨近端病理性骨折就诊。磁共振成像显示有一个侵袭性、膨胀性骨肿块,伴有皮质破坏和周围肌炎。计算机断层扫描引导下的活检组织学显示为单形性小圆形蓝细胞肿瘤。CD99免疫反应性以及通过断裂分离荧光原位杂交检测到的低水平EWSR1基因易位,最初支持尤因肉瘤的诊断并开始化疗。随后通过基于锚定多重聚合酶链反应的检测方法(Archer FusionPlex肉瘤检测板)进行分子评估,发现了核磷蛋白-间变性淋巴瘤激酶(NPM-ALK)基因融合。诊断随后修正为原发性骨ALK阳性间变性大细胞淋巴瘤,并相应调整了化疗方案。本报告说明了这种分子检测方法在正确诊断一种伪装成另一种肿瘤类型的非常罕见恶性肿瘤中的价值。